Integral Health Asset Management LLC Raises Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Integral Health Asset Management LLC boosted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 145.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 875,000 shares of the company's stock after purchasing an additional 519,000 shares during the quarter. Integral Health Asset Management LLC owned about 1.76% of Mineralys Therapeutics worth $10,771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in MLYS. BNP Paribas Financial Markets bought a new position in shares of Mineralys Therapeutics in the 4th quarter worth $48,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock worth $130,000 after buying an additional 989 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Mineralys Therapeutics in the 4th quarter worth $145,000. EntryPoint Capital LLC bought a new position in shares of Mineralys Therapeutics in the 4th quarter worth $154,000. Finally, AlphaQuest LLC increased its holdings in shares of Mineralys Therapeutics by 2,637.8% in the 4th quarter. AlphaQuest LLC now owns 15,222 shares of the company's stock worth $187,000 after buying an additional 14,666 shares during the last quarter. Institutional investors own 84.46% of the company's stock.

Analyst Ratings Changes

MLYS has been the topic of a number of research analyst reports. The Goldman Sachs Group decreased their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Guggenheim reissued a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $42.00 target price on shares of Mineralys Therapeutics in a report on Tuesday.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock traded down $0.01 on Friday, hitting $15.35. 779,188 shares of the company's stock traded hands, compared to its average volume of 469,430. Mineralys Therapeutics, Inc. has a one year low of $8.24 and a one year high of $18.38. The company's fifty day simple moving average is $14.29 and its 200 day simple moving average is $12.47. The stock has a market capitalization of $995.85 million, a price-to-earnings ratio of -4.22 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.23. As a group, sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 55,771 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total value of $878,950.96. Following the transaction, the insider now owns 116,704 shares in the company, valued at approximately $1,839,255.04. The trade was a 32.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Samsara Biocapital Gp, Llc bought 600,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were bought at an average cost of $13.50 per share, for a total transaction of $8,100,000.00. Following the purchase, the insider now directly owns 5,674,916 shares in the company, valued at approximately $76,611,366. This represents a 11.82% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 104,579 shares of company stock valued at $1,534,353. Insiders own 25.56% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.